Which regimens are preferred by the DHHS guidelines for treatment-naive patients with HIV infection?

Updated: Mar 05, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Current DHHS guidelines list the following regimens as preferred in treatment-naive patients [5] :

  • INSTI-based regimens are as follows:
    • Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) - only for patients who are HLA-B*5701–negative
    • DTG plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
    • Elvitegravir/cobicistat/TDF/FTC (EVG/c/TDF/FTC) - only for patients with pre-ART creatinine clearance (CrCl) of >70 mL/min
    • Raltegravir (RAL) plus TDF/FTC
  • The PI/r-based regimen is darunavir/ritonavir (DRV/r) plus TDF/FTC
  • HIV-2 is intrinsically resistant to NNRTIs and enfuvirtide.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!